AstraZeneca Pharma India Limited (NSE:ASTRAZEN)
9,226.50
+23.50 (0.26%)
At close: Dec 5, 2025
AstraZeneca Pharma India Employees
AstraZeneca Pharma India had 802 employees as of March 31, 2025. The number of employees decreased by 138 or -14.68% compared to the previous year.
Employees
802
Change (1Y)
-138
Growth (1Y)
-14.68%
Revenue / Employee
33.44M INR
Profits / Employee
3.32M INR
Market Cap
230.29B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 802 | -138 | -14.68% |
| Mar 31, 2024 | 940 | -7 | -0.74% |
| Mar 31, 2023 | 947 | -236 | -19.95% |
| Mar 31, 2022 | 1,183 | -100 | -7.79% |
| Mar 31, 2021 | 1,283 | -42 | -3.17% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Sun Pharmaceutical Industries | 43,000 |
| Apollo Hospitals Enterprise | 42,497 |
| Cipla | 30,313 |
| Zydus Lifesciences | 27,917 |
| Aurobindo Pharma | 27,707 |
| Mankind Pharma | 26,978 |
| Alkem Laboratories | 18,785 |
| Biocon | 16,315 |
AstraZeneca Pharma India News
- 18 days ago - AstraZeneca Pharma India jumps 3% after teaming up with Sun Pharma to boost access to Hyperkalaemia treatment in India - Business Upturn
- 19 days ago - AstraZeneca and Sun Pharma partner to boost access to Hyperkalaemia treatment in India - Business Upturn
- 7 weeks ago - AstraZeneca Pharma India to launch hyperkalemia treatment ‘Lokelma’ in November 2025 - Business Upturn
- 2 months ago - AstraZeneca Pharma India secures CDSCO approval for additional indication of Enhertu - Business Upturn
- 3 months ago - AstraZeneca Pharma receives Rs 60.49 crore NPPA show cause notice over Symbicort pricing - Business Upturn
- 4 months ago - AstraZeneca Pharma shares rise over 2% after company swings back to profit in Q1 - Business Upturn
- 4 months ago - AstraZeneca Pharma Q1 Results: Revenue up 36% YoY to Rs 526 crore, Net Profit at Rs 55 crore - Business Upturn
- 5 months ago - AstraZeneca Pharma gets CDSCO approval to import and sell Imfinzi for additional indication - Business Upturn